CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Regulation FD Disclosure

CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01. Regulation FD Disclosure.

A copy of a slide presentation that Caladrius Biosciences, Inc.
(the “Company”) will use at investor and industry conferences and
presentations is attached to this Current Report as Exhibit 99.1
and is incorporated herein solely for purposes of this Item 7.01
disclosure. The information in this Item 7.01, including Exhibit
99.1 attached hereto, is being furnished and shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of such section. The information in this Item
7.01, including Exhibit 99.1 attached hereto, shall not be
incorporated by reference into any filing under the Securities
Act of 1933, as amended or the Exchange Act, regardless of any
incorporation by reference language in any such filing. This Item
7.01 will not be deemed an admission as to the materiality of any
information in this Item 7.01 that is required to be disclosed
solely by Regulation FD.
Item 9.01. Financial Statement and Exhibits.>
(d) Exhibits.
Exhibit No.
Description
99.1
Caladrius Biosciences, Inc. Corporate Presentation,
June 2017


About CALADRIUS BIOSCIENCES, INC. (NASDAQ:CLBS)

Caladrius Biosciences, Inc., formerly NeoStem, Inc., through its subsidiary, PCT, LLC, a Caladrius Company (PCT), provides development and manufacturing services to the cell therapy industry (which includes cell-based gene therapy). PCT specializes in cell and cell-based gene therapies. PCT offers development and manufacturing capabilities, quality systems, cell and tissue processing, logistics, storage and distribution and engineering solutions to clients with therapeutic candidates at all stages of development. The Company’s product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company’s T Regulatory Cell Technology is applicable to multiple autoimmune and allergic diseases.

An ad to help with our costs